MedPath

UCB, Inc.

UCB, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
1987-01-01
Employees
501
Market Cap
-
Website
http://www.ucb-usa.com

MSD and Cyprumed Forge $493 Million Deal to Advance Oral Peptide Therapeutics

MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations.

UCB Launches Comprehensive Bimzelx Navigate Program to Enhance Patient Access and Support

UCB's Bimzelx Navigate program offers bridge access to therapy at $15 per dose for up to 2 years, addressing insurance coverage delays for commercially insured patients.

© Copyright 2025. All Rights Reserved by MedPath